<DOC>
	<DOC>NCT01703091</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy for advanced/metastatic disease.</brief_summary>
	<brief_title>A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>NonSmall Cell Lung Cancer disease Clinical stage IV or recurrent disease One prior firstline platinumbased chemotherapy regimen with or without maintenance therapy For NonSmall Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI) monotherapy (only one regimen in the setting of single use) should be utilized Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1 Adequate organ function Estimated life expectancy of at least 3 months. Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment Receiving concurrent treatment with other anticancer therapy Central nervous system disease other than stable and treated brain metastasis Has major blood vessel invasion or encasement by cancer Has intratumor cavitation Has a history of uncontrolled thrombotic disorder Is receiving therapeutic anticoagulation with drugs Is receiving chronic therapy with nonsteroidal antiinflammatory drugs Has a history of hemoptysis within 2 months prior to randomization Has clinically relevant congestive heart failure Has experienced any arterial thromboembolic event Has uncontrolled arterial hypertension Has had a serious or nonhealing wound or, ulcer Has significant existing conditions</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>